Using EEG to Predict Depression Treatment Response to rTMS in Patients With Major Depression

Last updated: June 24, 2024
Sponsor: Baptist Health South Florida
Overall Status: Trial Not Available

Phase

N/A

Condition

Depression (Major/severe)

Depression

Treatment

Electroencephalogram (EEG)

Clinical Study ID

NCT04575285
TMS Depression
  • Ages > 18
  • All Genders

Study Summary

Repetitive Transcranial Magnetic Stimulation (rTMS) is a promising, novel, non-invasive therapy for depression. The study is looking at changes in specific electroencephalogram parameters in depressed patients treated with rTMS can serve as predictors of depression treatment response among cancer patents undergoing rTMS treatment of depression.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosed with cancer

  • Comorbid diagnosis of major depressive disorder

  • Age ≥ 18 years

  • Baseline Hamilton Depression Rating Scale (HDRS) score ≥ 18

  • Failed one or more adequate antidepressant trials (including selective serotoninreuptake inhibitors or SSRIs, selective norepinephrine reuptake inhibitors or SNRIs,tricyclic antidepressants or TCAs). A failed treatment response may be due to lackof antidepressant efficacy or intolerable side effects.

Exclusion

Exclusion Criteria:

  • History of seizure or epilepsy

  • History of concussion

  • History of bipolar disorder

  • Comorbid psychotic disorder

  • Primary brain tumor or metastasis to brain

  • Active comorbid substance use disorder

  • History or current diagnosis of dementia

  • Current pregnancy

  • Unable to attend regular treatment sessions

  • Any other condition in which a physician investigator feels may subject theparticipant to undue risk

Study Design

Treatment Group(s): 1
Primary Treatment: Electroencephalogram (EEG)
Phase:
Study Start date:
April 01, 2020
Estimated Completion Date:
December 01, 2031

Study Description

The study will be a prospective, single arm trial in which a set of patients who will be treated for major depression using Repetitive Transcranial Magnetic Stimulation (according to FDA approved rTMS standard care practices) also will undergo EEG recording before Repetitive Transcranial Magnetic Stimulation treatment begins, and at the completion of treatment. The Hamilton Depression Rating Scale will be given to participants by the neuropsychiatrist at baseline and weekly intervals till the completion of treatment.

The neuropsychiatrist investigators expect to see about 12 patients per year who meet treatment criteria for Repetitive Transcranial Magnetic Stimulation. Therefore, it is expected to recruit 24 subjects into the research study over a two-year period.

Connect with a study center

  • Starlie C Belnap

    Miami, Florida 33176
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.